Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey R Oxnard

Showing results (141-150 of 199) with videos related to

Pageof 20
Sort By:
JCO Precision Oncology|October 20, 2022
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA SamplesHatim Husain, Dean C Pavlick, Bernard J Fendler, et al.
JCO Precision Oncology|July 12, 2022
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesAmado J Zurita, Ryon P Graf, Guillermo Villacampa, et al.
Cancer Discovery|October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung CancerMagda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Discrimination of Germline <i>EGFR</i> T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer PatientsYuebi Hu, Ryan S Alden, Justin I Odegaard, et al.
Nature Medicine|May 5, 2015
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MKenneth S Thress, Cloud P Paweletz, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Identification of a RAS-activating <i>TMEM87A-RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung CancerAlissa J Cooper, Yoshihisa Kobayashi, Dewey Kim, et al.
JAMA Oncology|August 4, 2018
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, et al.
European Urology|October 30, 2021
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate CancerRyon P Graf, Virginia Fisher, Joaquin Mateo, et al.
JTO Clinical and Research Reports|September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA GenotypingMarissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
JAMA Oncology|January 20, 2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging AnalysisLaurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Pageof 20

Showing results (141-150 of 199) with videos related to

Sort By:
Pageof 20
JCO Precision Oncology|October 20, 2022
Tumor Fraction Correlates With Detection of Actionable Variants Across > 23,000 Circulating Tumor DNA SamplesHatim Husain, Dean C Pavlick, Bernard J Fendler, et al.
JCO Precision Oncology|July 12, 2022
Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting TherapiesAmado J Zurita, Ryon P Graf, Guillermo Villacampa, et al.
Cancer Discovery|October 4, 2016
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung CancerMagda Bahcall, Taebo Sim, Cloud P Paweletz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2017
Discrimination of Germline <i>EGFR</i> T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer PatientsYuebi Hu, Ryan S Alden, Justin I Odegaard, et al.
Nature Medicine|May 5, 2015
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790MKenneth S Thress, Cloud P Paweletz, Enriqueta Felip, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2020
Identification of a RAS-activating <i>TMEM87A-RASGRF1</i> Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung CancerAlissa J Cooper, Yoshihisa Kobayashi, Dewey Kim, et al.
JAMA Oncology|August 4, 2018
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to OsimertinibGeoffrey R Oxnard, Yuebi Hu, Kathryn F Mileham, et al.
European Urology|October 30, 2021
Predictive Genomic Biomarkers of Hormonal Therapy Versus Chemotherapy Benefit in Metastatic Castration-resistant Prostate CancerRyon P Graf, Virginia Fisher, Joaquin Mateo, et al.
JTO Clinical and Research Reports|September 30, 2021
SPACEWALK: A Remote Participation Study of ALK Resistance Leveraging Plasma Cell-Free DNA GenotypingMarissa N Lawrence, Rubii M Tamen, Pablo Martinez, et al.
JAMA Oncology|January 20, 2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging AnalysisLaurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Pageof 20